Bellerophon Therapeutics Inc at JMP Securities Life Science Conference Transcript
All right. So we are going to go ahead and get started. Yes, okay. Great. So thank you for being with us again at the 2019 JMP Securities Life Science Conference. Excited to have next company presentation here from Bellerophon Therapeutics. Bellerophon is developing novel treatments for lung diseases including peripheral -- PAH.
So Fabian Tenenbaum, CEO, I will turn it over to you. Thank you for being here, Fabian.
Thank you very much, Jason. Thank you for having us. Before we begin, let me just remind everyone our presentation will contain forward-looking statements. For additional information on those statements, please review our periodical SEC filings.
Bellerophon therapeutics is a clinical stage biotherapeutics company. We are focused on developing inhaled nitric oxide therapies for chronic pulmonary hypertensive diseases. We've developed a unique, proprietary, portable drug delivery system for nitric oxide that provides us with unique
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)